Q3 2024 Zymeworks Inc Earnings Call Transcript
Key Points
- Zymeworks Inc (ZYME) received clearance for IND applications for DW 171 and DW 191, marking significant progress in their clinical development pipeline.
- The company reported a $2.5 million research milestone from GSK, validating the strength and versatility of their internal platforms and technologies.
- Zymeworks Inc (ZYME) completed the first $30 million of their share repurchase program, indicating confidence in their financial position and stock value.
- The company has a strong financial position with $374.9 million in cash resources, providing an expected cash runway into the second half of 2027.
- Zymeworks Inc (ZYME) is advancing their R&D pipeline with promising preclinical data and plans for IND filings for new ADCs in 2025.
- Zymeworks Inc (ZYME) reported a net loss of $99.2 million for the nine months ended September 30, 2024, indicating ongoing financial challenges.
- Revenue decreased to $45.3 million for the nine months ended September 30, 2024, compared to $59.1 million for the same period in 2023.
- The company recorded a noncash impairment charge of $17.3 million due to the discontinuation of the Zanata Manin Clinical Development Program.
- Operating expenses were $160.2 million for the nine months ended September 30, 2024, reflecting a high cost structure despite a decrease from the previous year.
- Zymeworks Inc (ZYME) faces uncertainties related to regulatory approvals and potential competition from other therapies in development.
Hello, thank you for standing by. This is the conference operator. Welcome to Zymework's first quarter, 2024 results conference call and webcast. As a reminder, all participants are on a listen-only mode and the conference is being recorded. (Operator Instructions)
I would now like to turn the conference over to Shrinal Inamdar, Director of Investor Relations. You may begin.
Thank you, Aperia.
Good afternoon, everyone. Thank you for joining our third quarter, 2024 results conference call.
Before we begin, I would like to remind you that we'll be making a number of forward-looking statements during this call, including without limitation, those four statements identified in our slides and in the accompanying oral commentary, forward-looking statements are based upon our current expectations and various assumptions and are subject to the usual risks and uncertainties associated with companies in our industry. And at our, at our stage of development for a discussion of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
